Get the Stockscreener App
14.77
1.72%
0.25
Pre-market:
15.16
0.39
+2.64%
Alpha Tau Medical Ltd stock is traded at $14.77, with a volume of 464.06K.
It is up +1.72% in the last 24 hours and up +0.48% over the past month.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
See More
Previous Close:
$14.52
Open:
$14.5
24h Volume:
464.06K
Relative Volume:
0.70
Market Cap:
$1.37B
Revenue:
-
Net Income/Loss:
$-56.88M
P/E Ratio:
-22.37
EPS:
-0.6604
Net Cash Flow:
$-39.43M
1W Performance:
-4.65%
1M Performance:
+0.48%
6M Performance:
+110.70%
1Y Performance:
+263.79%
1-Day Range:
$14.31
$14.80
1-Week Range:
$14.31
$15.62
52-Week Range:
$3.43
$15.79
Alpha Tau Medical Ltd Stock (DRTS) Company Profile
Compare DRTS vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRTS
Alpha Tau Medical Ltd
|
14.77 | 1.37B | 0 | -56.88M | -39.43M | -0.6604 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alpha Tau Medical Ltd Stock (DRTS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-26 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-15-23 | Initiated | Citigroup | Buy |
| Apr-24-23 | Initiated | H.C. Wainwright | Buy |
| Apr-14-22 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-22 | Initiated | Piper Sandler | Overweight |
| Apr-04-22 | Initiated | Citigroup | Buy |
View All
Alpha Tau Medical Ltd Stock (DRTS) Latest News
Alpha Tau Medical Ltd Balance Sheet – FWB:H44 - TradingView
Debt to assets ratio of Alpha Tau Medical Ltd – FWB:H44 - TradingView
Net income of Alpha Tau Medical Ltd – FWB:H44 - TradingView
Alpha Tau Medical stock trades at USD 15.30 - AD HOC NEWS
Alpha Tau Medical (DRTS) Reports Early Trial Progress, Is The Premium Already Priced In? - simplywall.st
Alpha Tau Medical Ltd.(NasdaqCM: DRTS) added to S&P Global BMI Index - marketscreener.com
Alpha Tau Medical stock holds steady as investors await next results - AD HOC NEWS
How Early Cancer Trial Results Will Impact Alpha Tau Medical Stock (DRTS) - simplywall.st
Alpha Tau Medical Ltd stock hits 52-week high at 15.2 USD - Investing.com Australia
Alpha Tau’s Cancer Trials Keep Beating Expectations. Three Major Data Readouts Are Next. By FinanceWire - Investing.com
Alpha Tau's Cancer Trials Keep Beating Expectations. Three Major Data Readouts Are Next. - Benzinga
DRTS Stock Gets A Pre-Market Boost – Retail Shrug Off Wider Q1 Loss Ahead Of Key Pancreatic Cancer Data Reveal This Week - Stocktwits
Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More (ORMP) - Seeking Alpha
Is Trial Enrollment Completion Altering The Investment Case For Alpha Tau Medical (DRTS)? - simplywall.st
Is IMPACT Pilot Enrollment Completion Reshaping The Investment Case For Alpha Tau Medical (DRTS)? - simplywall.st
Alpha Tau Medical stock hits 52-week high at 15.11 USD By Investing.com - Investing.com Australia
Alpha Tau Medical stock hits 52-week high at 15.11 USD - Investing.com
Alpha Tau: Approaching Massive Year-End; Pounding The Table On Potential GBM Breakthrough - Seeking Alpha
Alpha Tau Medical Ltd. Warrant (DRTSW) Key Financial Ratios – Valuation, Profitability & More - Value Research
Alpha Tau to Participate in September Investor Conferences - Alpha Tau Medical
H.C. Wainwright reiterates Alpha Tau Medical stock rating on trial enrollment By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Alpha Tau Medical stock rating on trial enrollment - Investing.com Nigeria
Alpha Tau Medical (DRTS) finishes pancreatic IMPACT study signup - Stock Titan
Alpha Tau’s pancreatic cancer study grows from 12 to 48 patients as enrollment closes - Stock Titan
Alpha Tau Medical Ltd. Warrant (DRTSW) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
Alpha Tau Medical Warrant (DRTSW) Rises 4.1% to $4.05 as Support HoldsStock Picks - careplusvn.com
Alpha Tau Medical (DRTS) officer schedules next stock sale under 10b5-1 plan - Stock Titan
Alpha Tau Medical (NASDAQ:DRTS) Sets New 1-Year HighHere's What Happened - MarketBeat
Alpha Tau Medical stock hits 52-week high at 14.79 USD - Investing.com
Alpha Tau’s Clinical Momentum Put Its Cancer Tech On The Map - Finimize
Price to sales forward of Alpha Tau Medical Ltd. – NASDAQ:DRTSW - TradingView
Price to earnings forward of Alpha Tau Medical Ltd. – NASDAQ:DRTSW - TradingView
Price to earnings forward of Alpha Tau Medical Ltd. – BOATS:DRTSW - TradingView
DRTS Stock Price, Quote & Chart - ChartMill
Is Alpha Tau Medical’s (DRTS) Steepening Loss Curve Reframing Its High-Risk Innovation Strategy? - simplywall.st
Alpha Tau Medical Ltd.: Fundamental Analysis and Financial Ratings | DRTS | IL0011839383 - marketscreener.com
Alpha Tau Medical (XTAE:DRTS) Cyclically Adjusted Price-to-FCF : (As of Aug. 15, 2026) - GuruFocus
Alpha Tau Medical (XTAE:DRTS) Shiller PE Ratio : (As of Aug. 21, 2026) - GuruFocus
DRTS Forecast — Price Target — Prediction for 2027 - tradingview.com
Q3 EPS Estimate for Alpha Tau Medical Decreased by Analyst - MarketBeat
Alpha Tau Medical Warrant (DRTSW) Surges 8.96% to $3.89 as Traders Target Key ResistanceTrend Continuation Trade - careplusvn.com
Alpha Tau Medical (NASDAQ:DRTS) Stock Price Down 5.4% Following Insider Selling - MarketBeat
Alpha Tau Medical (NASDAQ:DRTS) CFO Sells $248,220.00 in Stock - MarketBeat
H.C. Wainwright raises Alpha Tau Medical stock price target to $16 - Investing.com
Five Takeaways from AHNS 2026: Alpha DaRT in Combination with Immunotherapy for Advanced Head and Neck Cancer - Alpha Tau Medical
Alpha Tau Medical Ltd Stock (DRTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):